EGFR and non-small cell lung carcinoma: These findings led to Breakthrough Therapy Designation by FDA and will likely establish first-line osimertinib as a new standard of care for EGFR-mutant NSCLC, limiting the penetration in clinical practice of more recently developed strategies for TKI-naïve patients such as dacomitinib, a second-generation TKI [39], or the combination of erlotinib and bevacizumab [40].